With a PhD degree at Fudan University, China, in 2008 Xianjun Yu accepted a position of postdoctoral fellow in Department of Cancer Molecular Biology at Baylor College of Medicine where he initiated a study of pancreatic oncology. Next year, he was nominated a clinic observership at MD. Anderson Cancer Center. After he returned from USA, he was engaged as a Professor and Chair of Department of Pancreatic & Hepatobiliary Surgery of Shanghai Cancer Center at Fudan University. In 2012, he had set up the pancreatic Cancer Institute Fudan University and took charge of president of this institution. Over the last 10 years, Prof. Yu’s clinical practice has an emphasis on pancreatic cancer surgery and focused on the basic and translational research of the pancreatic cancer. The goal of his research is to improve the diagnosis and treatment of pancreatic cancer by the identification of disease specific molecules useful as biomarkers or therapeutic targets through various efforts. With his expertise in basic and translational research of the pancreatic cancer, he has innovated the pancreaticojejunostomy, developed the new type surgical instruments to significantly raise the surgery safety and reduce the treatment cost, revealed the characteristics of lymphatic metastasis of pancreatic cancer to standardize the lymphadenectomy, modified the protocol of the traditional comprehensive treatment, conducted the clinical research in order to provide the personalized surgical treatment for pancreatic cancer patients, filed a dozen of national patent applications, published numerous advanced SCI journal papers, edited/reviewed for many academic journals, worked as a vice president/editor in Cancer Letters Shanghai Office, coordinated/participated in several national and international cooperation projects including the National Science Fund for Distinguished Young Scholars (2016), served as a chairman designate of China Association for Anti-pancreatic Cancer Research, gave speech at international academic conferences such as annual meeting of International Association of Pancreatology (IAP) and Japan Society of Clinical Oncology (JSCO) and received many academic honors including Outstanding Achievements in Pancreatology (2015). Innovative, translational and longstanding research has ever been a pursuit in his academic career.